Drug intelligence / Profile preview

Lu AF90103

Development stage: Phase 1
Lead developer: Lundbeck
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Intravenous

Overview

Lu AF90103 (also known as compound 42e) is a methyl ester prodrug of compound 42d, developed to penetrate the blood-brain barrier. Compound 42d acts as a partial agonist at the GluN1/GluN2B complex of the NMDA receptor, with approximately 24% efficacy and an EC50 value of 78 nM. Lu AF90103 was designed to provide rapid and sustained antidepressant effects by targeting NMDA receptors, specifically aiming for fast-onset antidepressant activity without the psychotomimetic side effects associated with ketamine. The drug was developed by H. Lundbeck A/S and reached phase I clinical trials for depression but has since been discontinued[1][2][3][7].

Other names: 42e

Targets

GluR (Glutamate receptors)

Beyond the preview

Go deeper on Lu AF90103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lu AF90103.

Explore the full profile